CCSG Developmental Funds are critical to the continued growth and development of the Winship Cancer Institute (Winship). These funds provide a critical base of funding enabling Winship to advance its strategic plan by investing in the cancer center's highest priorities. Winship's initial type 1 CCSG award Included approximately $800,000 of Development Funds over three years, and these funds have supported Winship's pilot grant program and two developing shared resources, Bioinfonnatics and Transgenic Mouse Facility. Since April 2009, Winship has distributed 24 pilot grants directly linked to CCSG developmental funds. In addition, the Winship has allocated over $1 million in philanthropic funds for matching pilot grants during the same time period. In total, Winship has distributed over $1.4 million in pilot grant funding to its members to accelerate progress within their research programs, in this current application, Winship is requesting $437,818 in developmental funds per year primarily to continue its pilot grant program and to advance Winship's strategic initiatives through faculty recruitment. This would be allocated as $200,000/year for faculty recruitment in defined domains as identified by the Winship Strategic Plan 2010-2015. Another $200,000/year would continue to support the Winship Pilot Grant Program, with a particular focus on awards that Involve: 1. New Investigations in partnership with the Emory Chemical Biology Center;2. New initiatives in comparative effectiveness research In oncology;3. Research projects in conjunction with an NCI-supported cancer cooperative group or network;4. Research partnerships with investigators from another NCI-designated cancer center;or 5. Investigations in partnership with faculty from another research institution in Georgia. The current request for Developmental Funds in combination with the continued commitment of institutional funds will allow the Executive Director and his leadership team to continue the planned development in a number of strategic recruitments and research development. This support will enable Winship to move toward fulfilling its vision of being a transformative leader in the integration of cancer research, education, and care.

Public Health Relevance

The requested Developmental Funds will provide additional support for the continued growth and development by sponsoring faculty recruitment and pilot grants for the members of the Winship Cancer Institute.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
United States
Zip Code
Cornely, Ronald M; Schlingmann, Barbara; Shepherd, Whitney S et al. (2017) Two common human CLDN5 alleles encode different open reading frames but produce one protein isoform. Ann N Y Acad Sci 1397:119-129
Qi, Q; Kang, S S; Zhang, S et al. (2017) Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression. Oncogene 36:4562-4572
Zhong, Jim; Patel, Kirtesh; Switchenko, Jeffrey et al. (2017) Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer 123:3486-3493
Lee, Byoungkoo; Konen, Jessica; Wilkinson, Scott et al. (2017) Local alignment vectors reveal cancer cell-induced ECM fiber remodeling dynamics. Sci Rep 7:39498
Kim, Yong Joon; Kaluz, Stefan; Mehta, Anil et al. (2017) Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example. Bio Protoc 7:
Morris, Lydia P; Conley, Andrew B; Degtyareva, Natalya et al. (2017) Genome-wide map of Apn1 binding sites under oxidative stress in Saccharomyces cerevisiae. Yeast 34:447-458
Gavile, Catherine M; Barwick, Benjamin G; Newman, Scott et al. (2017) CD86 regulates myeloma cell survival. Blood Adv 1:2307-2319
Cassidy, Richard J; Liu, Yuan; Patel, Kirtesh et al. (2017) Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base. Cancer 123:783-793
Fei, Baowei; Guolan Lu; Halicek, Martin T et al. (2017) Label-free hyperspectral imaging and quantification methods for surgical margin assessment of tissue specimens of cancer patients. Conf Proc IEEE Eng Med Biol Soc 2017:4041-4045
Ivanov, A A; Gonzalez-Pecchi, V; Khuri, L F et al. (2017) OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc. Oncogene 36:5852-5860

Showing the most recent 10 out of 265 publications